KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EBIT: 2010-2025

Historic EBIT for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$31.7 million.

  • Nektar Therapeutics' EBIT rose 7.78% to -$31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.1 million, marking a year-over-year increase of 35.91%. This contributed to the annual value of -$105.2 million for FY2024, which is 60.10% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' EBIT is -$31.7 million, which was up 12.58% from -$36.2 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year EBIT high stood at $14.3 million for Q4 2024, and its period low was -$152.8 million during Q2 2022.
  • Its 3-year average for EBIT is -$43.8 million, with a median of -$36.2 million in 2025.
  • As far as peak fluctuations go, Nektar Therapeutics' EBIT slumped by 41.82% in 2021, and later spiked by 142.82% in 2024.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' EBIT stood at -$112.9 million in 2021, then skyrocketed by 53.53% to -$52.5 million in 2022, then spiked by 36.13% to -$33.5 million in 2023, then soared by 142.82% to $14.3 million in 2024, then increased by 7.78% to -$31.7 million in 2025.
  • Its EBIT stands at -$31.7 million for Q3 2025, versus -$36.2 million for Q2 2025 and -$44.5 million for Q1 2025.